Sign up

NEA Management Company, LLC

$1.6B assets · 26 holdings · Q2 2026 · Filed 14 AUG 2026

About NEA Management Company, LLC’s 13F portfolio

NEA Management Company, LLC is an institutional investment manager that discloses its US-listed holdings each quarter through an SEC Form 13F filing. As of , NEA Management Company, LLC reported $1.6B across 26 US-listed positions (). Its largest position is Trevi Therapeutics, Inc. (TRVI) at 16% of the reported book, and its ten biggest holdings make up 90% of the portfolio. Browse every manager in the fund managers directory, or see the legendary investors we track on the superinvestors page.

$1.6B
Assets (13F)
#1,763
of 8,845 by size
26
Holdings
90%
Top-10 weight
1
Buys
3
Sells
Top holdings · Q2 2026
26 total
#StockPrice% of portfolioSharesValue
1
NASDAQ: TRVI
Trevi Therapeutics, Inc.
$13.72
+1.55%
16%
13.2M$246.6M
2
NASDAQ: MBX
MBX Biosciences, Inc.
$53.41
−0.02%
13%
3.6M$199.5M
3
NASDAQ: GLUE
Monte Rosa Therapeutics, Inc.
$8.91
−1.76%
12%
7.7M$186.2M
4
NASDAQ: CELC
Celcuity Inc.
$56.31
+1.28%
11%
1.7M$179.0M
5
NASDAQ: SGP
Spyglass Pharma, Inc.
—
—
10%
7.4M$164.6M
6
NASDAQ: SVRA
Savara, Inc.
$5.21
+10.38%
9.5%
24.5M$150.7M
7
NASDAQ: ZBIO
Zenas BioPharma, Inc.
$25.04
−5.22%
6.4%
4.0M$102.1M
8
NYSE: COUR
Coursera, Inc.
$3.45
−3.63%
4.6%
12.9M$72.6M
9
NASDAQ: AUPH
Aurinia Pharmaceuticals, Inc.
$14.89
−1.59%
4.2%
4.0M$67.4M
10
NASDAQ: CRSP
CRISPR Therapeutics AG
$38.93
−3.14%
3.6%
1.1M$57.7M
11
NASDAQ: ORIC
ORIC Pharmaceuticals, Inc.
$7.70
+0.65%
2.8%
4.1M$44.6M
12
NASDAQ: PHAT
Phathom Pharmaceuticals, Inc.
$5.08
−4.15%
1.3%
2.0M$21.3M
13
NASDAQ: KRRO
Korro Bio, Inc.
$12.19
−2.01%
1.1%
1.3M$17.1M
14
NASDAQ: XFOR
X4 Pharmaceuticals, Inc.
$2.96
−0.67%
1.0%
3.2M$15.1M
15
NASDAQ: CSBR
Champions Oncology, Inc.
$4.40
−0.90%
0.7%
1.7M$10.6M
16
NASDAQ: NKTX
Nkarta, Inc.
$1.12
−2.61%
0.6%
3.6M$10.1M
17
NASDAQ: CVRX
CVRx, Inc.
$0.53
−11.77%
0.6%
2.0M$10.0M
18
NASDAQ: BDTX
Black Diamond Therapeutics, Inc.
$1.39
−2.80%
0.5%
4.4M$8.2M
19
NASDAQ: KPTI
Karyopharm Therapeutics Inc.
$0.02
−56.50%
0.4%
577K$5.6M
20
NASDAQ: IVA
Inventiva SA
$3.45
+1.77%
0.3%
1.5M$5.5M
21
NASDAQ: LONA
LeonaBio, Inc.
—
—
0.3%
464K$4.3M
22
NASDAQ: SNTI
Senti Biosciences, Inc.
$2.79
+3106.90%
0.3%
3.8M$4.2M
23
NASDAQ: MRKR
Marker Therapeutics, Inc.
$1.32
+54.71%
0.2%
1.6M$2.4M
24
NASDAQ: OKUR
OnKure Therapeutics, Inc.
$2.76
−2.13%
0.1%
479K$2.2M
25
NASDAQ: IMA
ImageneBio, Inc.
$3.98
+4.46%
0.0%
50K$295K

Showing 1–25 of 26 positions on this page reported in this 13F.

Sector allocation
  • Healthcare85%
  • Consumer Defensive4.6%
Recent activity · vs 2026-03-31
Bought1
  • NewKPTIKaryopharm Therapeutics Inc.—$5.6M
Sold3
  • ReducedCELCCelcuity Inc.−25.2%$179.0M
  • ReducedCVRXCVRx, Inc.−3.5%$10.0M
  • SoldACLXArcellx, Inc.−100%—

Reading NEA Management Company, LLC’s 13F portfolio

NEA Management Company, LLC’s $1.6B 13F book is spread across 26 reported positions and is highly concentrated — its ten largest positions alone are 90% of the portfolio. A book this concentrated means a small group of names drives most of its performance. Its five largest positions are TRVI, MBX, GLUE, CELC and SGP, led by Trevi Therapeutics, Inc. (TRVI) at 16% of the portfolio. The heaviest sector exposure is Healthcare (85%), then Consumer Defensive (5%).

What NEA Management Company, LLC changed last quarter

Between 2026-03-31 and Q2 2026, NEA Management Company, LLC was a net seller: it opened 1 new positions and added to 0 more, while trimming 2 and closing 1 outright. Against a 26-name book, that is moderate turnover, pointing to steady rotation within the portfolio. Its largest new or increased position was Karyopharm Therapeutics Inc. (KPTI), and its biggest reduction was Celcuity Inc. (CELC).

What a 13F does and doesn’t reveal

A 13F captures only NEA Management Company, LLC’s long positions in US-listed stocks at a single quarter-end, so it is best read as a lagged snapshot rather than a live portfolio. It won’t show shorts, cash, bonds, or holdings listed outside the US, and it never reveals the price paid or the reasoning behind a trade. The signal is in the pattern over time: which names NEA Management Company, LLC is building up, trimming, or exiting, and how concentrated the book stays from quarter to quarter.

Frequently asked questions

What is an SEC 13F filing?

A Form 13F is a report that every institutional investment manager with at least $100 million in US-listed securities must file with the SEC within 45 days of each quarter's end. It lists the manager's long positions in US-listed stocks and certain options, with the share count and market value of each. NEA Management Company, LLC's profile on this page is built directly from those filings.

How current is the 13F data on NEA Management Company, LLC's page?

It reflects NEA Management Company, LLC's most recently filed 13F, currently the quarter ending Q2 2026. Because managers have up to 45 days after a quarter closes to file, a 13F is always a slightly lagged view rather than a live portfolio. When NEA Management Company, LLC files its next quarterly report, this page refreshes automatically.

Can I see NEA Management Company, LLC's complete list of holdings?

This page highlights NEA Management Company, LLC's largest positions rather than all 26 names in the filing. The complete, position-by-position 13F is public and available from the SEC's EDGAR database under NEA Management Company, LLC's filings.

Does a 13F show everything NEA Management Company, LLC owns?

No. A 13F only covers long positions in US-listed stocks and certain options. It leaves out short positions, cash, bonds, commodities, foreign-listed stocks, and private holdings, so it is a partial view of NEA Management Company, LLC's book rather than its full strategy or total assets.

Is 13F data investment advice?

No. Everything here is educational. 13F positions are disclosed with a delay, cover only long US-listed holdings, and never explain why NEA Management Company, LLC made a trade or at what price. Treat it as a research lens, not a recommendation, and speak with a licensed financial advisor before making investment decisions.

Not investment advice. Holdings data comes from public SEC Form 13F filings, which are filed with a delay of up to 45 days and may be amended later. It describes historical, disclosed positions in US-listed securities only, meaning no shorts, cash, or foreign holdings, and it is not a recommendation. Always do your own research and speak with a licensed financial advisor before making investment decisions.